175 related articles for article (PubMed ID: 29601672)
1. MRI-guided interventional natural killer cell delivery for liver tumor treatment.
Su Z; Wang X; Zheng L; Lyu T; Figini M; Wang B; Procissi D; Shangguan J; Sun C; Pan L; Qin L; Zhang B; Velichko Y; Salem R; Yaghmai V; Larson AC; Zhang Z
Cancer Med; 2018 May; 7(5):1860-1869. PubMed ID: 29601672
[TBL] [Abstract][Full Text] [Related]
2. MRI-monitored transcatheter intra-arterial delivery of SPIO-labeled natural killer cells to hepatocellular carcinoma: preclinical studies in a rodent model.
Sheu AY; Zhang Z; Omary RA; Larson AC
Invest Radiol; 2013 Jun; 48(6):492-9. PubMed ID: 23249649
[TBL] [Abstract][Full Text] [Related]
3. Clinically applicable magnetic-labeling of natural killer cells for MRI of transcatheter delivery to liver tumors: preclinical validation for clinical translation.
Li K; Gordon AC; Zheng L; Li W; Guo Y; Sun J; Zhang G; Han G; Larson AC; Zhang Z
Nanomedicine (Lond); 2015; 10(11):1761-74. PubMed ID: 26080698
[TBL] [Abstract][Full Text] [Related]
4. MRI radiomics to monitor therapeutic outcome of sorafenib plus IHA transcatheter NK cell combination therapy in hepatocellular carcinoma.
Yu G; Zhang Z; Eresen A; Hou Q; Garcia EE; Yu Z; Abi-Jaoudeh N; Yaghmai V; Zhang Z
J Transl Med; 2024 Jan; 22(1):76. PubMed ID: 38243292
[TBL] [Abstract][Full Text] [Related]
5. Magneto-Activation and Magnetic Resonance Imaging of Natural Killer Cells Labeled with Magnetic Nanocomplexes for the Treatment of Solid Tumors.
Sim T; Choi B; Kwon SW; Kim KS; Choi H; Ross A; Kim DH
ACS Nano; 2021 Aug; 15(8):12780-12793. PubMed ID: 34165964
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin enhances NK cells immunotherapy efficacy to suppress HCC progression via altering the androgen receptor (AR)-ULBP2 signals.
Shi L; Lin H; Li G; Sun Y; Shen J; Xu J; Lin C; Yeh S; Cai X; Chang C
Cancer Lett; 2016 Apr; 373(1):45-56. PubMed ID: 26805759
[TBL] [Abstract][Full Text] [Related]
7. hIL-15 gene-modified human natural killer cells (NKL-IL15) augments the anti-human hepatocellular carcinoma effect in vivo.
Jiang W; Zhang C; Tian Z; Zhang J
Immunobiology; 2014 Jul; 219(7):547-53. PubMed ID: 24721706
[TBL] [Abstract][Full Text] [Related]
8. Pilot study to determine the safety and feasibility of deceased donor liver natural killer cell infusion to liver transplant recipients with hepatocellular carcinoma.
Ohira M; Hotta R; Tanaka Y; Matsuura T; Tekin A; Selvaggi G; Vianna R; Ricordi C; Ruiz P; Nishida S; Tzakis AG; Ohdan H
Cancer Immunol Immunother; 2022 Mar; 71(3):589-599. PubMed ID: 34282496
[TBL] [Abstract][Full Text] [Related]
9. Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma.
Kamiya T; Chang YH; Campana D
Cancer Immunol Res; 2016 Jul; 4(7):574-81. PubMed ID: 27197065
[TBL] [Abstract][Full Text] [Related]
10. Live cell imaging of highly activated natural killer cells against human hepatocellular carcinoma in vivo.
Uong TNT; Yoon MS; Lee KH; Hyun H; Nam TK; Min JJ; Nguyen HPQ; Kim SK
Cytotherapy; 2021 Sep; 23(9):799-809. PubMed ID: 34176769
[TBL] [Abstract][Full Text] [Related]
11. Adoptive transfer of TRAIL-expressing natural killer cells prevents recurrence of hepatocellular carcinoma after partial hepatectomy.
Ohira M; Ohdan H; Mitsuta H; Ishiyama K; Tanaka Y; Igarashi Y; Asahara T
Transplantation; 2006 Dec; 82(12):1712-9. PubMed ID: 17198265
[TBL] [Abstract][Full Text] [Related]
12. Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma.
Yu M; Luo H; Fan M; Wu X; Shi B; Di S; Liu Y; Pan Z; Jiang H; Li Z
Mol Ther; 2018 Feb; 26(2):366-378. PubMed ID: 29339014
[TBL] [Abstract][Full Text] [Related]
13. Transcatheter Intra-Arterial Infusion Combined with Interventional Photothermal Therapy for the Treatment of Hepatocellular Carcinoma.
Zhou J; Ling G; Cao J; Ding X; Liao X; Wu M; Zhou X; Xu H; Long Q
Int J Nanomedicine; 2020; 15():1373-1385. PubMed ID: 32184592
[TBL] [Abstract][Full Text] [Related]
14. A Phase I Study of Locoregional High-Dose Autologous Natural Killer Cell Therapy With Hepatic Arterial Infusion Chemotherapy in Patients With Locally Advanced Hepatocellular Carcinoma.
Bae WK; Lee BC; Kim HJ; Lee JJ; Chung IJ; Cho SB; Koh YS
Front Immunol; 2022; 13():879452. PubMed ID: 35720374
[TBL] [Abstract][Full Text] [Related]
15. Taste receptor T1R1/T1R3 promotes the tumoricidal activity of hepatic CD49a
Liu S; Xu M; Zhu C; Zhao Q; Zhou F
Eur J Immunol; 2018 Dec; 48(12):2031-2041. PubMed ID: 30259960
[TBL] [Abstract][Full Text] [Related]
16. Allogenic Natural Killer Cell Immunotherapy Combined with Irreversible Electroporation for Stage IV Hepatocellular Carcinoma: Survival Outcome.
Alnaggar M; Lin M; Mesmar A; Liang S; Qaid A; Xu K; Chen J; Niu L; Yin Z
Cell Physiol Biochem; 2018; 48(5):1882-1893. PubMed ID: 30092590
[TBL] [Abstract][Full Text] [Related]
17. Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy.
Sun C; Sun HY; Xiao WH; Zhang C; Tian ZG
Acta Pharmacol Sin; 2015 Oct; 36(10):1191-9. PubMed ID: 26073325
[TBL] [Abstract][Full Text] [Related]
18. Intraperitoneal delivery of human natural killer cells for treatment of ovarian cancer in a mouse xenograft model.
Geller MA; Knorr DA; Hermanson DA; Pribyl L; Bendzick L; McCullar V; Miller JS; Kaufman DS
Cytotherapy; 2013 Oct; 15(10):1297-306. PubMed ID: 23993303
[TBL] [Abstract][Full Text] [Related]
19. Kbtbd2 inhibits the cytotoxic activity of immortalized NK cells through down-regulating mTOR signaling in a mouse hepatocellular carcinoma model.
Dai K; Huang Y; Chen Z; Sun X; Yang L; Jiang Y
Eur J Immunol; 2018 Apr; 48(4):683-695. PubMed ID: 29331106
[TBL] [Abstract][Full Text] [Related]
20. Liver natural killer cell inoculum for liver transplantation with hepatocellular carcinoma.
Nishida S; Levi DM; Tzakis AG
Curr Opin Organ Transplant; 2013 Dec; 18(6):690-4. PubMed ID: 24220052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
